The Rhythm | Issue 11
Issue 11 | Week of 15 June 2026
No major cardiology congress fell this week. The most consequential evidence arrived through journal publication, and a single thread ran through it: a treatment can be mechanistically sound, biologically attractive, or statistically associated with benefit, and still fail when it is tested properly.
Cardiology Intelligence Briefing: plausible is not enough
This week cardiology kept running into the same wall. The clearest example came from resuscitation, where a drug given for decades to correct the acidosis of cardiac arrest did not improve the chance of restarting the heart and produced more metabolic derangement instead.1 A plausible physiological rationale, decades of habit, and a clean negative answer.
Elsewhere the lesson was about durability and proportion. A physiology-guided approach to coronary stenting, which uses a smarter reading of the angiogram to decide which narrowings to treat, held its advantage over five years, but almost all of that advantage was banked in the first two years and little accrued after that.2 Better measurement improved decisions, yet the long game added less than the headline implies.
Two papers showed how seductive a plausible mechanism can be. A vitamin shown to slow the build-up of calcium in coronary arteries moved its surrogate target, with no evidence yet that patients live longer or avoid events.3 And a cholesterol-lowering drug class associated with healthier ageing appeared to protect against frailty, but only after heavy statistical adjustment reversed what the raw data showed.5
The week's most practical message was that the hard problem is increasingly not whether a therapy works but whether it reaches patients and at what cost. Modelling of four-drug heart failure therapy suggested it offsets much of its own cost by keeping people out of hospital, while being honest that whether it saves money at all depends on what the drugs are priced at.4
Taken together, mechanism, surrogate movement, and association are promissory notes, not proof. The strongest evidence this week either closed a question by showing a plausible therapy does not work, or tempered an existing enthusiasm by showing where its benefit really sits. Preferring what has been demonstrated over what should be true is what separates durable practice from fashion.
